Merck's Keytruda-Padcev Combo Nears EU Approval for Bladder Cancer After Positive EMA Opinion
feedReported by Dow Jones Newswires
Sentiment
Positive
Importance
7
Price
$118.74
Mkt Cap
$286.203B
52W Low
$75.4
52W High
$125.14
Market data snapshot near publication time
summarizeSummary
Merck received a positive opinion from the EU's CHMP for its Keytruda-Padcev combination to treat a subset of bladder cancer patients. This recommendation is a key step towards market authorization in the EU for a new indication for Keytruda, a blockbuster drug. The combination is already approved in the U.S. A final decision from the European Commission is anticipated in Q3 this year.
At the time of this announcement, MRK was trading at $118.74 on NYSE in the Life Sciences sector, with a market capitalization of approximately $286.2B. The 52-week trading range was $75.40 to $125.14. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.